Frontier and ATSG launch global air network for temperature-controlled pharma
Frontier and ATSG launch a global cold-chain air network to ensure safe, temperature-controlled delivery of medicines.
Frontier Scientific Solutions and Air Transport Services Group (ATSG) have joined forces to transform the global delivery of temperature-sensitive pharmaceuticals. The strategic partnership introduces a dedicated air corridor designed for life sciences, ensuring continuous temperature control and full shipment integrity from origin to delivery.
The collaboration combines Frontier’s expertise as an end-to-end logistics integrator for life sciences with ATSG’s experience in air cargo transportation. Together, they will operate a purpose-built logistics network that meets the strict regulatory, operational, and security requirements of the pharmaceutical, biotechnology, and medical device industries. Frontier’s $1.5 billion investment from GID will support infrastructure development and network expansion, establishing a high-integrity platform for leading life science markets worldwide.
“The launch of our air network represents a major milestone in enhancing connected global infrastructure for life sciences,” said Steve Uebele, Chief Executive Officer of Frontier. “By linking Europe and the United States with additional strategic hubs under development, we are creating a logistics backbone that minimises handoffs, maintains temperature control, and delivers total visibility and compliance across every stage of the journey.”
The partnership introduces a dedicated fleet of temperature-controlled aircraft and validated global routes connecting key life science hubs, setting a new standard for precision and reliability in cold-corridor logistics. “Transforming how an industry moves and protects critical products is at the heart of what we do,” said Greg Mays, President of ATSG. “With over 40 years of experience in time-sensitive networks, we’ve created a dedicated solution for the highly regulated demands of the life sciences sector.”
Frontier’s operations reduce the typical 20 or more handoffs in traditional pharmaceutical supply chains to fewer than four. Its model combines cGDP-validated ground infrastructure, dedicated global airlift, and centralised quality oversight, operated by teams experienced in life sciences logistics, ensuring zero-loss, zero-excursion performance.
The company’s Wilmington, North Carolina air gateway serves as its North American headquarters, while Shannon, Ireland anchors operations across Europe, the Middle East, and Africa. Frontier plans further global expansion through 2026, developing additional hubs to serve major life science manufacturing and distribution markets.
The new air network will enable Frontier to create secure, compliant cold corridors worldwide, supporting the growing demand for biologics, GLP-1 therapies, and other temperature-sensitive treatments essential for patient care.
